Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia …

TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the prevention of ischemia and reperfusion injury (“IRI”) resulting from solid organ transplantation.

“We are very pleased to receive orphan drug designation for CBD in the prevention of IRI resulting from solid organ transplantation, such as liver, kidney, heart and lung, as it complements on our first FDA granted orphan drug designation for cannabidiol in the treatment of autoimmune hepatitis, a rare liver disease, and provides us with a unique cannabinoid pharmaceutical product pipeline that is in line with our overall ambition in becoming a leading global specialty medical cannabis company,” said

... read more at: https://globenewswire.com/news-release/2018/11/07/1646949/0/en/Revive-Therapeutics-Announces-FDA-Grants-Orphan-Drug-Designation-for-Cannabidiol-in-the-Prevention-of-Ischemia-and-Reperfusion-Injury-from-Organ-Transplantation.html

by

Leave a Reply